Final answer:
Acetaminophen does not qualify as a disease-modifying antirheumatic drug (DMARD) because it lacks the ability to alter the disease course or slow disease progression in rheumatic diseases, unlike Methotrexate, Hydroxychloroquine, and Infliximab.option d.
Step-by-step explanation:
Among the listed options, disease-modifying antirheumatic drugs (DMARDs) include Methotrexate, Hydroxychloroquine, and Infliximab. These are medications used to slow down the progression of rheumatic diseases by targeting the underlying mechanisms that cause inflammation and immune system dysfunction. Methotrexate is a commonly used DMARD, particularly for rheumatoid arthritis (RA), and works by inhibiting cells' ability to use folic acid, which is necessary for their growth. Hydroxychloroquine, originally an antimalarial medication, has been repurposed and is often used to treat RA and systemic lupus erythematosus (SLE) due to its anti-inflammatory properties. Infliximab is a biologic DMARD that targets specific components of the immune system to reduce inflammation.
On the other hand, Acetaminophen does not belong to the class of DMARDs. While it may be used to help manage pain and reduce fever, it does not change the disease process or slow disease progression in rheumatic diseases, which is a key difference from DMARDs. Thus, Acetaminophen is an example of an analgesic and antipyretic, but it is only weakly anti-inflammatory.